PISD

Across TCGA pan-cancer cohorts, PISD mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PISD data layer compared with 25 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PISD mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PISD expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

CCRCC, LSCC, and PDAC are the cancer types where PISD mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	IV	0.108	0.758	.024	9	view →
LSCC	OS	Median	All	1.000	0.936	.009	9	view →
PDAC	DFS	Quartile	III,IV	0.468	0.902	.018	4	view →
HNSC	OS	Tertile	III,IV	0.782	0.917	.039	3	view →
GBM	OS	Tertile	All	0.893	0.763	.045	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PISD–CCRCC (DFS)

Open the CCRCC breakdown →